Skip to main content
Wednesday 20 May 2026
BlueSky linkedin youtube
header links
  • Get Newsletters
  • Media Kit
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Equity and Sustainability
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • GLP-1
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO
    • BIO-Europe
    • C-Suite Innovators
    • ESMO
    • Frontiers Health
    • JP Morgan
    • Global Policy Insights
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
youtube linkedin BlueSky
Sign in

Haematology

News
BMS preps filings for leukaemia maintenance therapy CC-486

BMS preps filings for leukaemia maintenance therapy CC-486

News
Novartis' groundbreaking Kymriah

Real-world data backs Kymriah’s safety profile, says Novarti...

News
Red blood cells 3d illustration

LentiGlobin gene therapy for sickle cell on course for filin...

News
Calquence

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

News
Red blood cells moving in blood vessels with depth of field.

Novo Nordisk builds in haemophilia with Bluebird Bio gene ed...

News
Doptelet

Sobi stays on its acquisitive streak with $915m Dova deal

Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova

  • Load more results

Editor's Picks

  1. 'Seismic shift' as obesity overtakes cancer for R&D returns
  2. Bayer returns to M&A with $2.45bn Perfuse Therapeutics deal
  3. Lilly inflates US facility investment spending by $4.5bn
  4. Roche buys AI-powered diagnostics player PathAI
  5. Danco fights back after US court curbs abortion pill access
News
James Murray

Doctors dismayed by report of NHS AI proposal

The British Medical Association has branded a leaked proposal to rein back NHS recruitment and use more AI to compensate a "massive gamble."

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png
Digital
Discover a new era of healthcare panel engagement
Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Axtria Ignite 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Get Newsletters

 
 
youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company